UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | June 11, 2014 |
StemCells, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 000-19871 | 94-3078125 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 7707 Gateway Blvd, Suite 140, Newark, California | 94560 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 510.456.4000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 11, 2014, StemCells, Inc. (the “Company”) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”), at 2:00 p.m. local time, at the Company’s headquarters located at 7707 Gateway Blvd., Newark, California, pursuant to notice duly given. Only stockholders of record as of the close of business on April 17, 2014 were entitled to vote at the Annual Meeting. As of October 17, 2014, there were 55,495,192 shares of Company common stock outstanding and entitled to vote at the Annual Meeting, of which 39,947,412 shares of Company common stock were represented, in person or by proxy, constituting a quorum on all matters voted upon.
The final results of the stockholder vote on each proposal brought before the meeting were as follows:
Proposal Number 1 – The stockholders elected each of the two nominees to serve as Class II Directors for a three-year term expiring at the 2017 Annual Meeting.
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||||
Ricardo Levy, Ph.D |
7,267,989 | 372,404 | 0 | |||||||||
Irving Weissman, M.D |
7,228,936 | 411,457 | 0 | |||||||||
. |
||||||||||||
Proposal Number 2 – The stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||
38,292,591
|
1,079,859 | 574,962 | 0 | |||||||||
Proposal Number 3 – The stockholders approved the advisory vote on executive compensation
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||
6,385,939
|
1,046,380 | 208,074 | 32,307,019 | |||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| StemCells, Inc. | ||||
| June 13, 2014 | By: |
/s/ Kenneth Stratton
|
||
|
|
||||
| Name: Kenneth Stratton | ||||
| Title: General Counsel | ||||